Business Context and Reporting Period
Company: Deckers Outdoor Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1997
Business Overview: The Company designs, markets, and distributes footwear under the Teva(R), Simple(R), and Ugg(R) brands. Operations are seasonal, with sales volumes varying by product line and quarter.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 1997 | Nine Months Ended Sep 30, 1997 |
|---|---|---|
| Net Sales | $20,783,000 | $83,327,000 |
| Gross Profit | $7,330,000 (35.3% margin) | $34,812,000 (41.8% margin) |
| Net Earnings | $468,000 | $4,047,000 |
| Earnings Per Share (Diluted) | $0.05 | $0.45 |
| Cash and Equivalents | $8,449,000 (as of Sep 30, 1997) | |
| Working Capital | $32,745,000 (as of Sep 30, 1997) | |
| Long-Term Debt | $711,000 (excluding current maturities) | |
| Operating Cash Flow (9 months) | $18,642,000 |
Material Changes vs. Prior Period
- Revenue Trends:
- Three Months: Net sales decreased 11.5% ($2.7M) compared to the prior year. Teva(R) sales increased 22.2%, offset by declines in Simple(R) (down 26.2%) and Ugg(R) (down 11.3%).
- Nine Months: Net sales increased 4.4% ($3.5M). Teva(R) sales grew 24.7%, while Simple(R) and Ugg(R) declined 18.0% and 26.2%, respectively.
- Profitability:
- Three Months: Net earnings decreased 17.5% to $468,000. Gross margin compressed to 35.3% from 39.1% due to discounted Simple(R) sales.
- Nine Months: Net earnings increased 31.8% to $4.047M. Gross margin improved to 41.8% from 41.2%, driven by reduced Teva(R) close-outs and lower freight costs.
- Balance Sheet:
- Inventory: Decreased 42.6% to $14.3M due to seasonality and management efforts to reduce levels.
- Debt: The Company repaid all borrowings under its $25M revolving credit facility. Total debt is significantly reduced compared to the prior year.
Outlook, Risks, and Unusual Items
- Guidance: Management expects full-year 1997 sales for Simple(R) and Ugg(R) to be lower than 1996 levels. These declines are anticipated to be mitigated by increased Teva(R) sales.
- Unusual Items:
- Ugg Settlement: In September 1997, the Company settled arbitration with former Ugg shareholders. A final payment of $2.6 million is due on January 2, 1998, replacing future earn-out payments through 2000. This was recorded as a liability and an increase to goodwill.
- Factory Closure: A $500,000 loss on factory closure was recorded in the nine-month period.
- Risks:
- Consumer Preferences: Results are highly dependent on shifting consumer tastes, which could lead to obsolete inventory.
- Seasonality: Sales are concentrated in specific quarters (Teva in Q1/Q2, Simple in Q3, Ugg in Q4).
- Customer Dependence: Reliance on customers to carry and promote product lines.
- Liquidity: The Company has approximately $10.2M available under its credit facility and believes internal funds are sufficient for working capital needs.
Investor Verification Checklist
- Verify the impact of the $2.6M Ugg settlement payment due in January 1998 on future cash flows.
- Monitor the continued decline in Simple(R) and Ugg(R) sales volumes versus the growth trajectory of Teva(R).
- Assess inventory levels relative to the 42.6% reduction to ensure no future write-downs are necessary.
- Confirm compliance with financial covenants on the revolving credit facility, though currently in good standing.
- Review the adoption of SFAS 128 (Earnings Per Share) and SFAS 131 (Segment Reporting) in the fourth quarter of 1997 for potential changes in financial presentation.